Neo Comprehensive - Solid Tumor
Use
Neo Comprehensive - Solid Tumor (now NEO PanTracer Tissue) is a comprehensive next‑generation sequencing (NGS) solid tumor profiling assay designed for pan‑cancer indications. It detects genomic alterations including single nucleotide variants (SNVs), insertions/deletions (InDels), copy number variants (CNVs), fusions and splice variants by DNA and RNA sequencing, and assesses immunotherapy biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB), supporting diagnosis, therapy selection, prognosis, and clinical trial eligibility.
Special Instructions
A formalin‑fixed, paraffin‑embedded tissue block is preferred (>20% tumor, >10 mm² tumor surface area, ~500 tumor cells) with additional cells for PD‑L1 testing. If submitting unstained 5‑µm slides: for samples >25 mm²: 10 slides (2 sections each); for 10–24 mm²: 20 slides (2 sections each). Submit an additional H&E slide and 3 extra slides if PD‑L1 IHC is performed. Use a cold pack for transport, ensuring it does not touch the specimen. New York State clients must provide collection date and time.
Limitations
Not provided.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Block preferred (>10 mm2 tumor, >20% tumor). Unstained 5‑µm slides: ≥10 slides for >25 mm2; ≥20 slides for 10–24 mm2. Additional H&E and PD‑L1 slides as needed.
Storage Instructions
Use cold pack for transport (do not allow contact).